ARCHIVES

FDA Caps Advisors’ Holdings To $50,000 In Firms Affected By Committee Meetings.

This article is from The Cancer Letter archive.

Vol. 34 No. 31 | August 8, 2008

Download PDF Visit The Full Archive

Related Articles

DCT Adopts New Unsolicited Contract Review Procedures

May 21, 1976

UK’s NICE Set to Deny Payments For Zaltrap In Second-Line Metastatic Colorectal Cancer

June 26, 2013

New Evidence Shows Polyp Removal Lowers Death Rate at 23-Year Follow-up

February 24, 2012

FDA Accepts DCT Board’s Criteria For Approval Of New Drugs, Explains Plan for Early Action

February 17, 1989

South African Investigator Bezwoda Admits Falsifying Data In High-Dose Chemo Study.

February 11, 2000

CCIRC Reviews Two Existing, One Prospective Cooperative Group

March 4, 1977